RayKnowChina Research Map
Shortlist

RecruitingBreast cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer

An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Jiangsu Cancer Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorJiangsu Cancer Hospital江苏省肿瘤医院NanjingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07601178, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Prior treatment with any agent targeting the mechanism of tumor immunotherapy, including immune checkpoint inhibitors (e.g., anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-CTLA-4 antibodies), immune checkpoint agonists (e.g., antibodies targeting ICOS, CD40, CD137, GITR, OX40), or immune cell therapy.

    Exclusion criterion 9

  3. ECOG performance status 0 or 1.

    Inclusion criterion 8

  4. Platelet or red blood cell transfusion within 4 weeks before initiation of study drug treatment.

    Exclusion criterion 23

  5. At least one measurable tumor lesion according to RECIST 1.1 criteria.

    Inclusion criterion 6

  6. Known or self-reported human immunodeficiency virus (HIV) infection.

    Exclusion criterion 7

    HBV-DNA positive or HCV-DNA positive (copy number >10³).

    Exclusion criterion 8

    Presence of other malignancies within 5 years before enrollment, except for TNBC.

    Exclusion criterion 13

  7. Female participants who are pregnant, breastfeeding, or planning to become pregnant during the study.

    Exclusion criterion 25

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07601178, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Participants voluntarily join the study, sign the informed consent form, and agree to strictly comply with the study protocol requirements.
  • Female patients aged between 18 and 75 years.
  • Confirmed by histopathological examination as advanced triple-negative invasive breast cancer, meeting the following criteria: pathological type triple-negative, specifically: ER negative (IHC <1%), PR negative (IHC <1%), HER2 negative (IHC -/+ or IHC ++ but FISH/CISH negative). Priority is given to pathology from metastatic lesions; if metastatic lesion pathology is not available, primary lesion pathology may be used.
  • TNBC patients with initial diagnosis of stage IV (according to AJCC 8th edition) or recurrent/metastatic disease who are not suitable for surgery, and have not received prior systemic therapy for advanced disease. Prior neoadjuvant and/or adjuvant therapy with taxanes or other anti-tumor treatments is permitted, provided that there was no disease progression during neoadjuvant therapy, and the interval between completion of taxane-based (neo)adjuvant therapy and recurrence/metastasis is ≥6 months.
  • Suitable for nab-paclitaxel treatment.
  • At least one measurable tumor lesion according to RECIST 1.1 criteria.
  • Expected survival ≥3 months.
  • ECOG performance status 0 or 1.
  • Adequate organ function, including:

1)Hematology: Absolute neutrophil count (ANC) ≥1.5×10⁹/L; platelet count (PLT) ≥100×10⁹/L; hemoglobin (HB) ≥90 g/L.

2)Liver function: Total bilirubin ≤1.5×ULN; AST and ALT ≤2.5×ULN; if liver metastases are present, ALT and AST must be ≤5×ULN.

3)Renal function: Serum creatinine (Cr) ≤1.5×ULN, or creatinine clearance ≥60 mL/min (calculated by the Cockcroft-Gault formula).

10.Participants of childbearing potential must use appropriate contraception during the study and for 120 days after study completion, have a negative serum pregnancy test within 7 days before study enrollment, and must not be lactating.

Exclusion Criteria:

  • Known history of severe allergic reactions to QL1706, anlotinib, nab-paclitaxel, or any of their excipients.
  • Inability to swallow oral medications, or any gastrointestinal disorder that may interfere with the absorption and metabolism of the study drugs.
  • Symptomatic brain/leptomeningeal metastases and/or spinal cord metastases.
  • Active or potentially relapsing autoimmune disease, with the following exceptions: vitiligo, alopecia, psoriasis, or eczema not requiring systemic treatment; hypothyroidism due to autoimmune thyroiditis requiring only stable-dose hormone replacement therapy; type I diabetes mellitus requiring only stable-dose insulin replacement therapy.
  • Major surgery within 3 weeks before study initiation, or failure to recover from surgery.
  • History of organ transplantation or autologous/allogeneic stem cell transplantation.
  • Known or self-reported human immunodeficiency virus (HIV) infection.
  • HBV-DNA positive or HCV-DNA positive (copy number >10³).
  • Prior treatment with any agent targeting the mechanism of tumor immunotherapy, including immune checkpoint inhibitors (e.g., anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-CTLA-4 antibodies), immune checkpoint agonists (e.g., antibodies targeting ICOS, CD40, CD137, GITR, OX40), or immune cell therapy.
  • Prior treatment with anti-angiogenic targeted therapy.
  • Hypertension that cannot be well controlled with a single antihypertensive medication (systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥90 mmHg).
  • Arterial/venous thrombotic events (e.g., cerebrovascular accident including transient ischemic attack, deep vein thrombosis, pulmonary embolism) within 6 months before enrollment.
  • Presence of other malignancies within 5 years before enrollment, except for TNBC.
  • Tumor invasion or compression of surrounding major blood vessels or organs.
  • Active central nervous system (CNS) metastatic lesions.
  • Clinically significant pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
  • History of myocarditis, cardiomyopathy, or malignant arrhythmias.
  • History of significant bleeding tendency or coagulation dysfunction.
  • History of esophageal-gastric varices, severe ulcer, non-healing wound, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess, or acute gastrointestinal bleeding within 6 months before the first dose.
  • Known active tuberculosis (TB).
  • History of or current non-infectious pneumonitis/interstitial lung disease requiring systemic corticosteroid therapy.
  • Major surgery or severe trauma within 30 days before the first dose, or planned major surgery within 30 days after the first dose; minor local surgery within 3 days before the first dose.
  • Platelet or red blood cell transfusion within 4 weeks before initiation of study drug treatment.
  • Receipt of live vaccine within 4 weeks before the first dose, or planned receipt of live vaccine during the study.
  • Female participants who are pregnant, breastfeeding, or planning to become pregnant during the study.
  • Patients judged by the investigator to be unsuitable for participation in this study.

Quoted from ClinicalTrials.gov, NCT07601178, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07601178, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07601178